Cargando…
Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
The mainstay of treatment for opioid use disorder are medications, methadone (a full opioid agonist), or buprenorphine (a partial opioid agonist), in conjunction with psychosocial interventions. Both treatments are effective but safety, efficacy, and patient preference can lead to a decision to chan...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919996/ https://www.ncbi.nlm.nih.gov/pubmed/33870954 http://dx.doi.org/10.1097/ADM.0000000000000854 |
_version_ | 1784669034523918336 |
---|---|
author | Hill, Duncan Hayes, Victoria Demirkol, Apo Lintzeris, Nicholas |
author_facet | Hill, Duncan Hayes, Victoria Demirkol, Apo Lintzeris, Nicholas |
author_sort | Hill, Duncan |
collection | PubMed |
description | The mainstay of treatment for opioid use disorder are medications, methadone (a full opioid agonist), or buprenorphine (a partial opioid agonist), in conjunction with psychosocial interventions. Both treatments are effective but safety, efficacy, and patient preference can lead to a decision to change from one treatment to the other. Transfer from buprenorphine to methadone is not clinically challenging; however, changing from methadone to buprenorphine is more complex. Published reports describe varied approaches to manage this transfer to both minimize patient symptoms associated with withdrawal from methadone and reduce risk of precipitating withdrawal symptoms with introduction of the partial agonist buprenorphine [Lintzeris et al. J Addict Med. 2020; in press]. There is no single approach for methadone to buprenorphine that is superior to others and no approach that is suitable for all case presentations. This case conference describes three different approaches to achieve a successful methadone to buprenorphine transfer and provides commentary on how the case may be managed based on published transfer “strategies.” |
format | Online Article Text |
id | pubmed-8919996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-89199962022-03-18 Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine Hill, Duncan Hayes, Victoria Demirkol, Apo Lintzeris, Nicholas J Addict Med Reviews The mainstay of treatment for opioid use disorder are medications, methadone (a full opioid agonist), or buprenorphine (a partial opioid agonist), in conjunction with psychosocial interventions. Both treatments are effective but safety, efficacy, and patient preference can lead to a decision to change from one treatment to the other. Transfer from buprenorphine to methadone is not clinically challenging; however, changing from methadone to buprenorphine is more complex. Published reports describe varied approaches to manage this transfer to both minimize patient symptoms associated with withdrawal from methadone and reduce risk of precipitating withdrawal symptoms with introduction of the partial agonist buprenorphine [Lintzeris et al. J Addict Med. 2020; in press]. There is no single approach for methadone to buprenorphine that is superior to others and no approach that is suitable for all case presentations. This case conference describes three different approaches to achieve a successful methadone to buprenorphine transfer and provides commentary on how the case may be managed based on published transfer “strategies.” Lippincott Williams & Wilkins 2022 2021-04-15 /pmc/articles/PMC8919996/ /pubmed/33870954 http://dx.doi.org/10.1097/ADM.0000000000000854 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Reviews Hill, Duncan Hayes, Victoria Demirkol, Apo Lintzeris, Nicholas Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine |
title | Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine |
title_full | Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine |
title_fullStr | Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine |
title_full_unstemmed | Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine |
title_short | Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine |
title_sort | clinical case conference: strategies for transferring from methadone to buprenorphine |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919996/ https://www.ncbi.nlm.nih.gov/pubmed/33870954 http://dx.doi.org/10.1097/ADM.0000000000000854 |
work_keys_str_mv | AT hillduncan clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine AT hayesvictoria clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine AT demirkolapo clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine AT lintzerisnicholas clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine |